Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeyondSpring's Plinabulin Designated "National Major Product" in China

publication date: Dec 4, 2017

BeyondSpring announced that China has designated Plinabulin a 2017 National Science and Technology Major Project. The designation implies speeded-up regulatory review and priority approval status in China. Plinabulin is currently being tested in a global Phase III clinical trial (with a large China arm) in patients with non-small cell lung cancer (NSCLC) and Phase II/III clinical program to prevent chemotherapy-induced neutropenia (CIN). BeyondSpring is a virtual company headquartered in New York City and a strong connection to China. More details....

Stock Symbol: (NSDQ: BYSI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.